ReviewCurrent cardiology reports2021
Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.
Review in Current cardiology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- AVS-referenced diagnostic performance ofFrontiers in endocrinology · 2026Pooled it
- Risk factors for persistent hypertension in primary aldosteronism after surgery: a systematic review and meta-analysis.Frontiers in physiology · 2025Pooled it
- Optimizing the diagnosis of primary aldosteronism: The role of adrenal vein sampling and the need for high-expertise reference centers.Journal of neuroendocrinology · 2026Observational
- Primary aldosteronism and long-term outcomes using PAMO definition.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Diagnostic value of saline infusion test-derived biochemical parameters for primary aldosteronism subtyping.Frontiers in endocrinology · 2026Article
- Primary aldosteronism and obstructive sleep apnea in hypertension: interplay, target organ damage, and clinical management.Frontiers in endocrinology · 2026Review
- Primary Aldosteronism Surgery Outcomes Under Current Blood Pressure Guidelines.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026Article
- Multimodality Imaging in Aldosterone-Induced Cardiomyopathy: Early Detection and Prognostic Implications.Diagnostics (Basel, Switzerland) · 2025Review
- Primary aldosteronism patients with bilateral adrenal vein sampling success achieve better outcomes through unilateral adrenalectomy.Translational andrology and urology · 2025Article
- Typing diagnostic value ofEndocrine · 2025Article
- The value of targeted CXCR4Frontiers in endocrinology · 2025Article
- The impact of a primary aldosteronism predictive model in secondary hypertension decision support.JAMIA open · 2024Article
- First, a seat; then, an upgrade.Journal of human hypertension · 2024Article
- Clinical value ofEJNMMI research · 2024Article
- Lethal Arrhythmia Induced by Severe Hypokalemia with Primary Aldosteronism: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2024Review
- What We Know about and What Is New in Primary Aldosteronism.International journal of molecular sciences · 2024Review
- Cross-Disciplinary Approach of Adrenal Tumors: Insights into Primary Aldosteronism-Related Mineral Metabolism Status and Osteoporotic Fracture Risk.International journal of molecular sciences · 2023Review
- Key to the Treatment of Primary Aldosteronism in Secondary Hypertension: Subtype Diagnosis.Current hypertension reports · 2023Review
- Article
- Anatomical and functional remodeling of left ventricle in patients with primary aldosteronism and concomitant albuminuria.Therapeutic advances in chronic disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewPrimary aldosteronism (PA) is the most common cause of secondary hypertension and is significantly under-diagnosed. Delays in diagnosis and treatment can lead to cardiovascular morbidity and mortality. The goal of this study is to review the management of PA, with a focus on medical and surgical treatment outcomes. RECENT
findingsPA causes cardiovascular dysfunction in excess of degree of hypertension. Adrenalectomy demonstrates a therapeutic advantage over mineralocorticoid antagonist (MRA) therapy, after controlling for degree of hypertension and subtype of PA. Higher rates of atrial fibrillation, heart failure, stroke, and incidence of chronic kidney disease are observed in subjects treated with MRAs than in subjects treated with adrenalectomy. The therapeutic benefit of surgery may reflect definitive resolution of excess aldosterone. Complete mineralocorticoid blockade may achieve similar benefit to adrenalectomy. Adrenalectomy is the most effective treatment for unilateral PA. Biomarkers for MRA therapy might inform optimal medical therapy of bilateral adrenal hyperplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.